AIM - AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM Opportunity event on Wednesday, March 20, 2024 at 12:00 PM ET.

As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview, business outlook, and discuss the AIM opportunity.

A live video webcast of the presentation will be available on the Events page of the Company’s website ( aimimmuno.com ). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook .

Investor Contact:JTC Team, LLCJenene Thomas(833) 475-8247AIM@jtcir.com